Prediction of precipitation-induced phlebitis:: A statistical validation of an in vitro model

被引:29
作者
Johnson, JLH [1 ]
He, Y [1 ]
Yalkowsky, SH [1 ]
机构
[1] Univ Arizona, Dept Pharmaceut Sci, Tucson, AZ 85721 USA
关键词
phlebitis; precipitation; validation; in vitro model; intravenous;
D O I
10.1002/jps.10396
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To avoid phlebitis, new intravenous (IV) parenterals are often screened by injection into animals. This method is not only expensive and time consuming, it is also detrimental to the animals. An alternate method, focusing on precipitation as the cause, uses an in vitro dynamic injection model that requires less money and time and reduces the need for live models. Validation of the dynamic injection apparatus, for predicting mechanical phlebitis, is established. Twenty-one currently marketed IV products were injected into isotonic Sorenson's phosphate buffer flowing at 5 mL/min. The resulting opacities, produced by. precipitation, are measured in an ultraviolet flow cell. These opacity data, coupled with literature reports on phlebitis occurrence, were used to generate a logistic regression that indicates the probability of phlebitis given an opacity value measured by the apparatus. Regression results are supported by a receiver operator characteristic curve that establishes the most ideal cut-off opacity value. This opacity value provides the highest combined sensitivity (statistical power) and specificity while minimizing false-positive and false-negative results. Both analyses show that an opacity value of 0.003 best delineates phlebitic and nonphlebitic products. Measures of sensitivity (0.83), specificity (0.93), positive predictive value (0.93), and negative predictive value (0.78) indicate the model's predictive accuracy and reliability. These results support the use of the dynamic model in place of animals for preliminary phlebitis testing of new IV injectables. (C) 2003 Wiley-Liss, Inc. and the American Pharmacists Association.
引用
收藏
页码:1574 / 1581
页数:8
相关论文
共 23 条
  • [11] ROWLAND M, 1995, CLIN PHARMACOKINET, P138
  • [12] *STAT CORP, STATAQUEST 4 STAT SO
  • [13] PRECIPITATION OF PH SOLUBILIZED PHENYTOIN
    SURAKITBANHARN, Y
    SIMAMORA, P
    WARD, GH
    YALKOWSKY, SH
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 109 (01) : 27 - 33
  • [14] Sweetana S, 1996, PDA J Pharm Sci Technol, V50, P330
  • [15] TRISSEL LA, 2001, HDB INJECTABLE DRUGS, pR14
  • [16] TURCO SJ, 1987, PARENTERALS, V5, P1
  • [17] TURCO SJ, 1979, STERILE DOSAGE FORMS, P407
  • [18] Vorbach H, 1998, ADV EXP MED BIOL, V431, P827
  • [19] WARD GH, 1993, J PARENT SCI TECHN, V47, P161
  • [20] LOCAL DERMAL HYPERSENSITIVITY FROM DOBUTAMINE HYDROCHLORIDE (DOBUTREX SOLUTION) INJECTION
    WU, CC
    CHEN, WJ
    CHENG, JJ
    HSIEH, YY
    LIEN, WP
    [J]. CHEST, 1991, 99 (06) : 1547 - 1548